However, when pooling all target mutations (<i>KRAS, NRAS</i> and <i>BRAF</i>), the overall sensitivity and specificity were lower, at 48.3% and 51.1%, respectively.<h4>Conclusion</h4>The results of this study indicate that the ddPCR analysis of ctDNA may provide complementary information for the molecular diagnosis of CRC patients. This evidence concerns the gene KRAS and colorectal carcinoma.